Evidence map›Paper›PMID 36529623›Full record

Trial reportThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2023

Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition.

Hanadi Ajam Oughli, Marie Anne Gebara, Adam Ciarleglio, Helen Lavretsky, Patrick J Brown, Alastair J Flint, Nuri B Farber, Jordan F Karp, Benoit H Mulsant, Charles F Reynolds and 4 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pharmacotherapy of major depressive disorder in older adults: from an evidence-informed stepwise algorithm to precision medicine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  3. Remission is insufficient: predictors and mechanistic models of recurrence in late-life depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Optimizing treatment for older adults with depression.Therapeutic advances in psychopharmacology · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Hanadi Ajam OughliDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA.
Marie Anne GebaraDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA. Electronic address: gebarama@upmc.edu.
Adam CiarleglioDepartment of Biostatistics and Bioinformatics, Milken Institute School of Public Health, the George Washington University, Washington, DC.
Helen LavretskyDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA.
Patrick J BrownDepartment of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY.
Alastair J FlintDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Centre for Mental Health, University Health Network, Toronto, Canada.
Nuri B FarberDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO.
Jordan F KarpDepartment of Psychiatry, College of Medicine-Tucson, University of Arizona, Tucson, AZ.
Benoit H MulsantDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Centre for Addiction and Mental Health, Toronto, Canada.
Charles F ReynoldsDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA.
Steven P RooseDepartment of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY.
Lei YangDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO.
Meryl A ButtersDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA.
Eric J LenzeDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO.
University of Pittsburgh · USWashington University in St. Louis · USNeurobehavioral Systems · USNew York State Psychiatric InstituteMilken Institute · USUniversity Health Network · CAUniversity of Arizona · USUniversity of Toronto · CA

Funding

PHARMacist and Community Health Support to Optimize Medications After Trauma Surgery (PHARM-C)P50MH122351 · NIMH · WASHINGTON UNIVERSITY · PI Eric J Lenze · 2021 to 2026
$10.8M
Mentoring and Research in Translational Science of Integrative MedicineK24AT009198 · NCCIH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Helen Lavretsky · 2016 to 2026
$1.4M
Statistical and Machine Learning Methods for Integrating Clinical and Multimodal Imaging Data to Select Optimal Antidepressant TreatmentK01MH113850 · NIMH · GEORGE WASHINGTON UNIVERSITY · PI CIARLEGLIO, ADAM · 2018 to 2021
$647k
NCCIH NIH HHS K24 AT009198NIMH NIH HHS K01 MH113850NIMH NIH HHS P50 MH122351
6 · The paper itself

Abstract

objectiveEvidence-based treatment options for late-life treatment-resistant depression (TRD) are limited. Ketamine is a promising treatment for TRD; however, there is a paucity of data on its safety and efficacy in older adults.

methodsIn this pilot clinical trial, 25 adults aged ≥60 years with TRD received IV ketamine openly twice a week for 4 weeks; partial responders at the end of this acute phase were eligible to receive weekly infusions for 4 more weeks in a continuation phase. Acceptability, tolerability, and safety, including adverse and serious adverse events (AEs and SAEs), blood pressure changes, dissociation, craving, in addition to rates of depression response and remission were evaluated. The NIH Toolbox Cognitive Battery was used to assess specific measures of executive function (EF) and overall fluid cognition.

resultsCompletion rates were 88% for the acute phase and 100% for the continuation phase. No AEs resulted in participant discontinuation, and there were no SAEs. Treatment-emergent elevation of blood pressure, dissociation, and craving were transient and did not result in any participant discontinuation. Depressive symptoms improved significantly and 48% of participants responded. During the acute phase, the EF measures and the fluid cognition composite score improved (Cohen's d = 0.61), and these improvements were sustained in the continuation phase.

conclusionThis pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD. These promising findings need to be confirmed and extended in a larger randomized controlled trial.

Indexed as

KetamineAgedCognitionDepressionHumansInfusions, IntravenousPilot ProjectsKetaminecognitiongeriatricintravenous ketamineTreatment-resistant depression

Identifiers

PMID36529623
PMCPMC10839705
OpenAlexW4310722509

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.